TrialMatch® Links People with Dementia, Clinical Studies

trialmatch_rgb_4c copy

Did you know that the Alzheimer’s Association offers a service called Alzheimer’s Association TrialMatch® that assists people with Alzheimer’s disease and other forms of dementia, their families, and caregivers participate in clinical trials?

TrialMatch®, which is available at no charge and is confidential, provides participants with comprehensive clinical trial information. As the name implies, the service matches people with Alzheimer’s disease and related forms of dementia with existing clinical studies. To date, TrialMatch® has matched more than 11,000 people to Alzheimer’s clinical trials based on their diagnosis, preferences, and location.

TrialMatch® is easily accessible 24 hours a day at TrialMatch Specialists are available via telephone at 800-272-3900, Monday-Friday, 8:00 a.m. – 8:00 p.m. Central time.

The specialists at TrialMatch® will not recommend any particular clinical trial, but will describe all studies for which the person is eligible. They will answer questions about the trial process and connect individuals with trial sites based on their unique profiles.

The Alzheimer’s Association created TrialMatch® because recruiting and retaining participants for clinical studies is one of the greatest obstacles to developing the next generation of Alzheimer treatments. Those with dementia diseases, as well as healthy individuals are needed for a variety of studies. The immediate need for advances in diagnosis, treatment and prevention has led to an unprecedented call for clinical study participants.

Since the service launched in July 2010, more than 85,000 individuals have registered for Alzheimer’s clinical trials. Currently, Alzheimer’s Association TrialMatch® lists 250 research studies with 1000+ local trial sites nationwide.

Changing the Trajectory of Alzheimer’s Disease: How a Treatment by 2025 Saves Lives and Dollars


Recommended Federal Funding Would be Recouped within First Three Years of an Alzheimer’s Treatment Becoming Available

The U.S. could save $220 billion within the first five years of a treatment for Alzheimer’s disease being introduced, according to a new report from the Alzheimer’s Association. The Alzheimer’s Association report, Changing the Trajectory of Alzheimer’s Disease: How a Treatment by 2025 Saves Lives and Dollars, takes an in-depth look at the potential lives saved and positive economic impact if a hypothetical treatment that effectively delays the onset of Alzheimer’s disease is discovered and made available to Americans by 2025. The report shows that meeting the 2025 goal of the national Alzheimer’s plan would reduce the number of individuals affected by the disease by 2.5 million within the first five years of a treatment being available.

“Alzheimer’s disease is a triple threat, with soaring prevalence, lack of treatment and enormous costs, that no one can afford,” said Harry Johns, president and CEO of the Alzheimer’s Association. “If we’re going to change the current trajectory of the disease, thus saving lives and money, we need consistent and meaningful investments in research from the federal government.”

The report reinforces the value of reaching the 2025 goal set by the National Plan to Address Alzheimer’s Disease mandate by the National Alzheimer’s Project Act (NAPA). If the federal government were to invest $2 billion per year as recommended by the scientific community, then it would recoup its investment within the first three years after a treatment became available.

“Promising research is ready for the pipeline, and leading scientists believe the national goal is attainable if we accelerate federal funding,” said Johns. “With millions of lives and trillions of dollars at stake, we need real progress in the fight against Alzheimer’s.”

The Impact of Introducing a Hypothetical Treatment in 2025

A treatment introduced in 2025 that delays the onset of Alzheimer’s would cut the number of people in 2050 who have the disease by 42% – from 13.5 million to 7.8 million.

While delaying onset, finding a cure and saving lives are the most important goals, bringing some financial relief to the health care system and those affected by the disease is also a top priority. Under the Alzheimer’s Accountability Act, Congress has required the National Institutes of Health (NIH) to submit a professional judgment budget to Congress every fiscal year until 2025 to help guide them in allocating funding for Alzheimer’s research.

The Alzheimer’s Association’s report shows the positive impact of adequate funding and the potential consequences of under-funding.

• In 2015, the costs to all payers for the care of people living with Alzheimer’s disease and other dementias will total an estimated $226 billion, with Medicare and Medicaid paying 68 percent of the costs. Without a treatment costs are projected to increase to more than $1.1 trillion in 2050.

• Reaching the 2025 goal would save payers $220 billion over five years and $367 billion in the year 2050 alone. Savings to Medicare and Medicaid would account for nearly 60 percent of the savings.

• People living with Alzheimer’s and other dementias and their families would save $54 billion over the first five years in their out-of-pocket costs if the 2025 goal is met.

The Alzheimer’s Association is working closely with the federal government to ensure the plan and goals outlined under NAPA are being executed and met. A full text of the Alzheimer’s Association Changing the Trajectory of Alzheimer’s Disease: How a Treatment by 2025 Saves Lives and Dollars can be viewed at

Why I Run – Matt Brotherton


My name is Matt Brotherton and I am training and will ultimately run in the 119th Boston Marathon on April 20, 2015 in memory of my Grandmother who suffered from Alzheimer’s during the last 6 years of her life.

Alzheimer’s is a cause close to my heart, so I am training hard and will run over 500 training miles so I can run for Alzheimer’s – for awareness and to raise funds.

Alzheimer’s is a brutally devastating disease that causes problems with memory, thinking and behavior.

I hope to raise $5,000 for Alzheimer’s research and support services!

If you would like to support my efforts, you can contribute at



Alzheimer’s Accountability Act Incorporated into Funding Bill Signed into Law
Alzheimer’s Association Statement – Washington, D.C., December 17, 2014

As the largest Alzheimer’s advocacy organization in the world, the Alzheimer’s Association, and its relentless advocates, applaud Congress for creating a formal process to ensure that scientific judgment will guide them in future Alzheimer’s research funding decisions. This critical provision comes from the Alzheimer’s Accountability Act (H.R. 4351/S. 2192), which was fully incorporated within the fiscal year 2015 funding bill signed into law by the President.

Because of this action, Congress will be equipped with the best information to determine necessary Alzheimer’s research funding levels in each year leading up to 2025 to achieve the primary goal of the National Plan to Address Alzheimer’s Disease, creating a means to prevent and effectively treat Alzheimer’s disease.

“In setting funding levels, Congress has told us that they want to hear directly from the nation’s top scientists. That’s exactly what the Alzheimer’s Accountability Act does by connecting scientists with appropriators,” said Harry Johns, president and CEO of the Alzheimer’s Association. “The Alzheimer’s Association urged the introduction and passage of this Act so that Congress understands what science will bring us to the day when there will be survivors of Alzheimer’s, just as there now are for the other major diseases in our country.”

Introduced in April, the Alzheimer’s Accountability Act calls for the National Institutes of Health (NIH) to submit a Professional Judgment Budget for Alzheimer’s disease research each year until 2025 to achieve annual research milestones established under the National Alzheimer’s Plan. It will reflect the state of Alzheimer’s knowledge and the required investments in research identified by leading scientists to achieve the plan’s 2025 objective.

With the Alzheimer’s Accountability Act, Congress has created a mechanism that will utilize rigorous scientific judgment, rather than shifting political interests and unforeseen events, to guide Congressional funding allocations to achieve the 2025 goal.

Alzheimer’s Association grassroots advocates and staff held thousands of congressional meetings to secure support for the Alzheimer’s Accountability Act since the bill’s introduction. While the Alzheimer’s Association and its sister organization, the Alzheimer’s Impact Movement, were the only two organizations to endorse and work to advance the Alzheimer’s Accountability Act, the legislation received strong, bipartisan support in both the House and the Senate.

In addition to the Alzheimer’s Accountability Act, the funding bill included a $25 million increase for Alzheimer’s research, which comes on the heels of an unprecedented $122 million increase for Alzheimer’s research, education, outreach and caregiver support in fiscal year 2014.

Together, these increases bring annual federal funding for Alzheimer’s research to $591 million. However, scientists have stated that accomplishing the goal of the National Alzheimer’s Plan will require a commitment of at least $2 billion a year.

“According to leading experts, we must dramatically increase research funding to accomplish the primary goal of the National Alzheimer’s Plan to prevent and effectively treat Alzheimer’s by 2025. The Alzheimer’s Accountability Act will ensure that Congress hears directly from scientists what they will need to successfully achieve the federal government’s goal,” said Johns. “We now eagerly look forward to the President’s fiscal year 2016 budget with the tools in place to implement urgently needed, significant increases in Alzheimer’s funding to finally stop the human and economic devastation it causes.”

There are currently more than 5 million Americans living with Alzheimer’s disease at a cost to the nation of $214 billion a year, according to the Alzheimer’s Association 2014 Alzheimer’s Disease Facts and Figures report. Though Alzheimer’s is not normal aging, because advancing age is the greatest risk factor and Americans are living longer than ever before, those numbers are projected to soar to as many as 16 million by 2050, costing the nation $20 trillion over the next 40 years.

For more information on Alzheimer’s disease and available resources, visit the Alzheimer’s Association at

Erin Heintz, 202.638.7040;
Alzheimer’s Association Media Line, 312.335.4078,

Alzheimer’s Findings Seen as a Possible New Window to Understanding the Disease

Scientists at the Mayo Clinic have discovered a possible new link between an abnormal protein in the brain and the onset of Alzheimer’s disease, a breakthrough that could open new avenues to understanding the disease and finding effective treatments.

Abnormal forms of the protein, which assists DNA in coding and building new proteins inside the cell, appear to increase the atrophy of regions of the brain important to memory. And it could be a trigger of some kind, perhaps independently initiating the onset of Alzheimer’s-related dementia when combined with two other proteins whose abnormalities have long been implicated in the disease.

These findings, and more, were presented during the recently concluded six-day Alzheimer’s Association International Conference, AAIC, in Copenhagen.

AAIC is the world’s largest conference of its kind, bringing together researchers from around the world to report and discuss groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer’s disease and related disorders.

To read more about the Mayo Clinic discovery, click here.

To see all the 2014 AAIC video highlights, click here.